NCT03988920View on ClinicalTrials.gov

A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP

PHASE4CompletedINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

June 15, 2019

Primary Completion Date

June 26, 2021

Study Completion Date

July 31, 2021

Conditions
HyperphosphatemiaEnd Stage Renal Disease
Interventions
DRUG

Tenapanor

NHE3 Inhibitor

DRUG

Sevelamer Carbonate

Phosphate binder

Trial Locations (1)

77099

Ardelyx Site #509, Houston

Sponsors

Lead Sponsor

Ardelyx
All Listed Sponsors
lead

Ardelyx

INDUSTRY